Clinical trials: End Stage Renal Failure
ESRD (End-Stage Renal Disease), Kidney Transplantation
Study to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRD
The purpose of this study is to evaluate the safety and efficacy of the GGTA1 KO Thymokidney in patients with end-stage renal disease (ESRD) who are either not eligible for conventional allogeneic kidney transplantation (Group 1)…
- Conditions
- ESRD (End-Stage Renal Disease), Kidney Transplantation, Xenotransplantation
- Trial name
- EXTEND (NCT07224763)
- Testing
- GGTA1 KO Thymokidney
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- United Therapeutics
End Stage Renal Disease, Dialysis
Peritoneal Membrane Dysfunction in Peritoneal Dialysis Using Metabolomics
Ability and sensitivity of metabolomics analysis to highlight biomarkers or a score of biomarkers that will be able to identify those pediatric patients on peritoneal dialysis at high risk for possible peritoneal dialysis…
- Trial name
- NCT03964701
- Testing
- no intervention
- Where
- Greece
- Volunteers
- 18 people
- Sponsor
- Baxter (Hellas) Ltd
Secondary Hyperparathyroidism
Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease
The purpose of this study is to evaluate the effects of cinacalcet on markers of bone turnover in patients with kidney disease who are receiving dialysis.
- Trial name
- BONAFIDE (NCT00261950)
- Testing
- Sensipar (Cinacalcet HCl)
- Where
- 55 sites in United States, Belgium and 10 more
- Volunteers
- 110 people
- Sponsor
- Amgen
Diabetes Mellitus, Type 2, Diabetic Nephropathy
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
The goal of this study is to assess whether canagliflozin has a renal and vascular protective effect in reducing the progression of renal impairment relative to placebo in participants with type 2 diabetes mellitus (T2DM), Stage…
- Trial name
- CREDENCE (NCT02065791)
- Testing
- Canagliflozin
- Where
- 575 sites in United States, Argentina and 32 more
- Volunteers
- 4,401 people
- Sponsor
- Janssen Research & Development, LLC
Kidney Failure, Chronic
Observational Study to Evaluate the Time to Achieving the Maintenance Dose of Zemplar® (Paricalcitol Injection) in the Treatment of Patients Suffering From End-stage Renal Disease and Severe Over-reactivity of the Parathyroid Glands
This observational study will evaluate the clinical benefit of Zemplar (paricalcitol injection) in daily routine practice in end-stage renal disease patients with severe over-reactivity of parathyroid glands.
- Trial name
- NCT01273597
- Where
- 11 sites in Hungary
- Volunteers
- 60 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Chronic Renal Disease
Real-word Study of the de NOVO Extended-release tacrolimuS in Kidney Transplantation Using an ARTificial Intelligence
The purpose of this study is to assess the clinical efficacy of the LCPT En-varsus [Life-Cycle Pharma Tacrolimus] initiated in de novo (Day 0 of transplantation) using the Biopsy Proven Acute Re-jection and iBox (full and…
- Trial name
- NOVOSTART (NCT06960824)
- Testing
- Life-Cycle Pharma Tacrolimus, Kidney transplantation
- Where
- France
- Volunteers
- 165 people
- Sponsor
- Chiesi SAS
Kidney Failure, Chronic, End-Stage Kidney Disease
A Study to Evaluate the Effect of MK-5684 in Male Participants With Severe Renal Impairment (RI) and With End-stage Renal Disease (ESRD) (MK-5684-010)
The goal of the study is to learn what happens to levels of MK-5684 in people with severe renal impairment and end-stage renal disease versus a healthy person's body over time.
- Conditions
- Kidney Failure, Chronic, End-Stage Kidney Disease, Renal Failure, Chronic, Renal Failure, End-Stage
- Trial name
- NCT06814132
- Testing
- MK-5684, Prednisone, Fludrocortisone acetate
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Uremic Pruritus
CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
This is a multicenter, international study to evaluate the safety and efficacy of intravenous (IV) CR845 at a dose of 0.5 mcg/kg administered after each dialysis session.
- Trial name
- KALM-2 (NCT03636269)
- Testing
- CR845 0.5 mcg/kg
- Where
- 92 sites in United States, Australia and 9 more
- Volunteers
- 473 people
- Sponsor
- Cara Therapeutics, Inc.
Chronic Kidney Disease, End-Stage Renal Disease
The Effect of Somatropin Treatment in Adult Patients on Chronic Dialysis
This trial is conducted in Africa, Asia, Europe, North and South America and Oceania. The aim of the trial is to evaluate the effect of somatropin (human growth hormone) on survival (primary end-point; "time to death" and health…
- Trial name
- OPPORTUNITY (NCT00503698)
- Testing
- somatropin
- Where
- 381 sites in United States, Argentina and 19 more
- Volunteers
- 712 people
- Sponsor
- Novo Nordisk A/S
Stenosis of Vascular Prosthetic Devices, Implants and Grafts
Post-Approval Study for the FLAIR Endovascular Stent Graft
The purpose of this study is to confirm the long-term safety and effectiveness of the FLAIR Endovascular Stent Graft for treatment of stenoses at the venous anastomosis of ePTFE or other synthetic arteriovenous (AV) access grafts.
- Trial name
- RENOVA (NCT00677235)
- Testing
- FLAIR Endovascular Stent Graft, PTA
- Where
- United States
- Volunteers
- 270 people
- Sponsor
- C. R. Bard
Kidney Disease, Chronic, End Stage Kidney Disease
An Observational Study of Patients With Chronic Kidney Disease
TARGET-KIDNEY is an observational research study to conduct a comprehensive review of outcomes for patients with chronic kidney disease (CKD) and end-stage renal disease (ESKD).
- Trial name
- NCT05774392
- Testing
- Observational
- Sponsor
- Target PharmaSolutions, Inc.
End Stage Renal Disease, Inflammation
Permeability Enhancement to Reduce Chronic Inflammation
Chronic dialysis patients with end stage renal disease have an increased mortality rate as compared to the age matched healthy population.
- Trial name
- PERCI (NCT01582893)
- Testing
- HCO1100, P210H
- Where
- 2 sites in Germany
- Volunteers
- 50 people
- Sponsor
- Vantive Health LLC
Anemia
A Study of NeoRecormon (Epoetin Beta) in Patients With End Stage Renal Disease.
This single arm study will determine the effects of complete anemia correction in anemic patients with end-stage renal disease currently receiving suboptimal doses of NeoRecormon.
- Trial name
- NCT00413101
- Testing
- epoetin beta [NeoRecormon]
- Where
- Serbia
- Volunteers
- 50 people
- Sponsor
- Hoffmann-La Roche
End Stage Renal Disease
New Needle for Two-Needle Hemodialysis
Our preliminary studies have demonstrated that an innovative new design of the hemodialysis venous needle (the needle that returns the cleaned blood from the hemodialysis filter to the patient) with three jets is superior to the…
- Trial name
- BME-1 (NCT01416896)
- Testing
- Hemodialysis using the standard venous needle, Hemodialysis using a new venous needle, the "BME needle"
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Biomedical Enterprises Inc
Secondary Hyperparathyroidism, End-stage Kidney Disease (ESKD)
Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-1
This study is to evaluate the efficacy and safety of PLS240 in patients with hemodialysis-dependent end stage kidney disease (ESKD) and secondary hyperparathyroidism (SHPT). The study consists of two phases.
- Trial name
- PATH-1 (NCT05832931)
- Testing
- PLS240, Open-Label Extension PLS240
- Where
- 68 sites in United States, Bulgaria and 4 more
- Volunteers
- 362 people
- Sponsor
- Pathalys Pharma
Renal Failure
AURORA: Crestor 10mg Versus Placebo in Subjects With End-stage Renal Disease (ESRD)
The purpose of this study is to see if rosuvastatin helps to reduce the number of heart attacks, strokes and cardiovascular deaths in patients undergoing haemodialysis.
- Trial name
- NCT00240331
- Testing
- 10mg Rosuvastatin
- Where
- 239 sites in Australia, Austria and 23 more
- Volunteers
- 2,776 people
- Sponsor
- AstraZeneca
End Stage Renal Disease
Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients
The purpose of this study is to compare the clinical safety and efficacy of SFP in sparing the need for erythropoiesis stimulating agents (ESAs) required to maintain hemoglobin (hgb) levels in chronic hemodialysis subjects who…
- Trial name
- PRIME (NCT01286012)
- Testing
- Soluble Ferric Pyrophosphate in liquid bicarbonate, Erythrocyte Stimulating Agent (ESA), Intravenous (IV) Iron
- Where
- 23 sites in United States, Puerto Rico
- Volunteers
- 108 people
- Sponsor
- Rockwell Medical Technologies, Inc.
Kidney Failure, Chronic, Hemodialysis
Phase III Clinical Study of Recombinant Erythropoiesis Stimulating Protein Injection (rESP) in the Treatment of Anemia in Hemodialysis Patients With Chronic Renal Failure
To verify the efficacy of recombinant erythropoiesis stimulating protein injection (CHO cell) in hemodialysis patients with chronic renal failure anemia maintenance treatment is not inferior to yibio.
- Trial name
- NCT05211167
- Testing
- Human Erythropoiesis Injection (CHO cell), Recombinant Erythropoiesis Stimulating Protein Injection(CHO cell)
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Diabetic Nephropathy
To Determine the Effects of Avosentan on Doubling of Serum Creatinine, End Stage Renal Disease and Death in Diabetic Nephropathy
The purpose of this study is to determine whether avosentan (SPP301) is effective in decreasing morbidity and mortality in patients with diabetic nephropathy.
- Trial name
- NCT00120328
- Testing
- SPP301
- Where
- United States
- Volunteers
- 2,364 people
- Sponsor
- Speedel Pharma Ltd.
Chronic Renal Failure Requiring Hemodialysis
A Phase 3, Long-Term Safety Study of Intravenous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin
The purpose of the study is to determine the long-term safety in treatment-emergent adverse events (TEAEs) of intravenous (IV) administration of Epoetin Hospira for maintenance of target hemoglobin (Hgb) levels in patients…
- Trial name
- AiME - 03 (NCT01628107)
- Testing
- Epoetin Hospira
- Where
- 110 sites in United States, Puerto Rico
- Volunteers
- 406 people
- Sponsor
- Pfizer